| 王友君,李素欣,冯丽倩,王苗,李栋梁.地西他滨治疗骨髓增生异常综合征的疗效及对CDH1和P15甲基化、生存质量的影响.[J].中南医学科学杂志.,2024,(5):772-775. |
| 地西他滨治疗骨髓增生异常综合征的疗效及对CDH1和P15甲基化、生存质量的影响 |
| Efficacy of decitabine in the treatment of myelodysplastic syndrome and its influence on CDH1, P15 methylation and quality of life |
| 投稿时间：2023-06-28 修订日期：2024-08-18 |
| DOI：10.15972/j.cnki.43-1509/r.2024.05.019 |
| 中文关键词: 地西他滨 MDS 疗效 甲基化 生存质量 |
| 英文关键词:dexitabine MDS curative effect methylation quality of life |
| 基金项目:河北省医学科学研究课题(20221711) |
|
| 摘要点击次数: 0 |
| 全文下载次数: 0 |
| 中文摘要: |
| 目的探讨地西他滨治疗骨髓增生异常综合征(MDS)的疗效及对钙黏附分子1(CDH1)和P15甲基化水平、生存质量的影响。 方法选择75例MDS患者,按治疗方法分为对照组(37例,CAG化疗)和观察组(38例,CAG化疗+地西他滨)。比较两组临床疗效、血小板计数、血红蛋白、白细胞计数、CDH1、P15甲基化水平、生存质量、不良反应发生率。 结果观察组客观缓解率高于对照组(P＜0.05)。两组不良反应总发生率比较差异无显著性(P＞0.05)。与治疗前比较,治疗后两组血小板计数、血红蛋白、白细胞计数升高；CDH1、P15甲基化水平、情绪功能、伴随情况、主要症状、认知程度、满意程度评分降低；且观察组较对照组变化更显著(P＜0.05)。 结论地西他滨治疗MDS疗效显著,下调体内甲基化水平,改善生存质量；且不会增加不良反应发生风险。 |
| 英文摘要: |
| AimTo investigate the efficacy of decitabine in the treatment of myelodysplastic syndrome (MDS) and its effects on the methylation level of calcium adhesion molecule 1 (CDH1) and P15 and quality of life. MethodsSeventy-five MDS patients were randomly divided into control group (37 cases with CAG chemotherapy) and observation group (38 cases with CAG chemotherapy + decitabine). The clinical efficacy, platelet count, hemoglobin, white blood cell count, methylation levels of CDH1 and P15, quality of life and incidence of adverse reactions were compared between the two groups. ResultsThe objective remission rate of observation group was higher than that of control group (P＜0.05). There was no significant difference in the total incidence of adverse reactions between the two groups (P＞0.05). Compared with before treatment, the platelet count, hemoglobin, and white blood cell count increased in both groups after treatment; the methylation levels of CDH1 and P15, emotional function, accompanying conditions, main symptoms, cognitive level, and satisfaction score decrease; and the changes in the observation group were more significant than those in the control group (P＜0.05). ConclusionDecitabine is effective in the treatment of MDS to downregulate the methylation level in vivo and improve the quality of life. It does not increase the risk of adverse reactions, and has a high clinical reference value. |
| 查看全文 查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|